z-logo
open-access-imgOpen Access
Safety and Efficacy of Fixed Combination Travoprost-Timolol in the Lowering of Intraocular Pressure
Author(s) -
Robert J. Noecker,
Michael J. Pokabla
Publication year - 2010
Publication title -
clinical medicine insights therapeutics
Language(s) - English
Resource type - Journals
ISSN - 1179-559X
DOI - 10.4137/cmt.s2030
Subject(s) - travoprost , timolol , intraocular pressure , glaucoma , latanoprost , medicine , ocular hypertension , combination therapy , ophthalmology , dosing , fixed dose combination , pharmacology
The fixed combination eye drop Duotrav is a combination of travoprost 0.004% and timolol maleate 0.5%. Both travoprost and timolol have been used separately for the treatment of glaucoma by lowering intraocular pressure. Multiple studies have demonstrated the efficacy and safety of the fixed combination travoprost/timolol for the treatment of open-angle glaucoma and ocular hypertension. The once daily dosing of this combination offers multiple potential advantages such as patient adherence, potential cost advantages, and reduction in exposure to preservatives. This article discusses the benefits of fixed combination medications and summarizes past and recent studies listed on the online resource PubMed of the fixed combination travoprost/timolol with comparison to both monotherapy and other similar fixed combination ocular hypotensive preparations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom